NCT02660944 - A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 3, 2016

Primary Completion Date

May 28, 2020

Study Completion Date

August 10, 2020

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

RSLV-132

RNase-Fc fusion protein

DRUG

Placebo

Saline placebo

Trial Locations (16)

11030

Feinstein Institute for Medical Research, Manhasset

11042

Northwell Health/ Division of Rheumatology, Great Neck

19140

Temple University, Philadelphia

28210

DJL Clinical Research, Charlotte

33309

Center for Rheumatology, Immunology and Arthritis, Fort Lauderdale

33765

Clinical Research of West Florida, Clearwater

34102

Alper Research, Naples

37232

Vanderbilt University, Nashville

44195

Cleveland Clinic, Cleveland

75231

Metroplex Clinical Research Center, Dallas

77479

Accurate Clinical Research, Sugar Land

80045

University of Colorado, Aurora

90048

Wallace Rheumatic Study Center, Los Angeles

90720

Valerius Research Center, Los Alamitos

92020

TriWest Research Associates, El Cajon

92093

University of California San Diego, La Jolla